Gene therapy in an era of emerging treatment options for hemophilia B.

Abstract excerpt

Factor IX deficiency (hemophilia B) is less common than factor VIII deficiency (hemophilia A), and innovations in therapy for hemophilia B have generally lagged behind those for hemophilia A. Recently, the first sustained correction of the hemophilia bleeding phenotype by clotting factor gene therapy has been described using recombinant adeno-associated virus (AAV) to deliver factor IX. Despite this success, many...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Dependovirus
• Share to Factor IX
• Share to Gene Transfer Techniques